MedTrace Logo

Efficacy and Safety of Mycophenolate Mofetil in subjectswithSjogren's Syndrome

NCT02691949 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2016-09-23

No results posted yet for this study

Summary

Past literature showed encouraging effects of mycophenolate on dryness symptoms and quality of life in patients with Sjogren's syndrome. Mycophenolate also has excellent immunomodulation effects in lupus nephritis. Currently Mycophenolate is only used in lupus nephritis and organ transplant. It is unknown whether low dosage of mycophenolate mofetil could be used to improve ocular dryness and oral dryness in patients with Sjogren's syndrome.

Conditions

  • Sjogren's Syndrome

Interventions

DRUG

Mycophenolate mofetil

mycophenolate mofetil 1# BID-2# BID

Sponsors & Collaborators

  • Kaohsiung Medical University

    lead OTHER

Principal Investigators

  • Jeng-Hsien Yen · Kaohsiung Medical University

  • Wen-Chan Tsai · Kaohsiung Medical University

  • Tsan-Teng Ou, MD · Kaohsiung Medical University

  • Cheng-Chin Wu, MD · Kaohsiung Medical University

  • Wan-Yu Sung, MD · Kaohsiung Medical University

  • Chia-Chun Tseng, MD · Kaohsiung Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-29
Primary Completion
2018-04-30
Completion
2018-04-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02691949 on ClinicalTrials.gov